BioFocus announced has entered into collaboration with Almac allowing BioFocus customers with compound screening and profiling requirements to access Almac’s FLEXYTETM fluorescence lifetime (FLT) assays.
Integrating the assay technology allows BioFocus to offer an FLT platform that will complement its current target class capabilities, provide access to previously inaccessible epigenetic targets and offer alternative approaches to fragment-based screens and kinetic profiling.
“Being able to incorporate FLT assays in our service offering enables BioFocus to provide clients with an approach to screening and profiling that will unlock significant potential within their drug discovery efforts” commented Dr Kate Hilyard, VP Biological Sciences, BioFocus.
”We are delighted that BioFocus has chosen to add our FLEXYTETM technology to their service offering. We feel that this will allow a broad range of drug discovery groups access to the power of FLT,” said Dr Stephen Barr, President and Managing Director of Almac Sciences.
For more information, www.biofocus.com
Integrating the assay technology allows BioFocus to offer an FLT platform that will complement its current target class capabilities, provide access to previously inaccessible epigenetic targets and offer alternative approaches to fragment-based screens and kinetic profiling.
“Being able to incorporate FLT assays in our service offering enables BioFocus to provide clients with an approach to screening and profiling that will unlock significant potential within their drug discovery efforts” commented Dr Kate Hilyard, VP Biological Sciences, BioFocus.
”We are delighted that BioFocus has chosen to add our FLEXYTETM technology to their service offering. We feel that this will allow a broad range of drug discovery groups access to the power of FLT,” said Dr Stephen Barr, President and Managing Director of Almac Sciences.
For more information, www.biofocus.com
